Second-Line Treatment Strategies and Emerging Challenges

Dr. Zeidner explores second-line treatment selection complexity arising from frontline agent diversity and failure mechanism variability. Treatment decisions require consideration of initial agent choice (imatinib, second-generation, or asciminib), failure reason (intolerance versus resistance), and resistance mutation profiles when applicable.

Dr. Cortes emphasizes asciminib's value as second-line therapy, particularly following second-generation tyrosine kinase inhibitor resistance where it represents his preferred option. Post-imatinib failure scenarios allow either second-generation agents or asciminib, though he favors asciminib based on superior efficacy expectations despite limited second-line data from relatively small studies with abbreviated follow-up periods.

Decision complexity increases with frontline asciminib usage becoming more prevalent, creating uncertainty about optimal second and third-line strategies post-asciminib failure. Limited experience and data regarding specific agent performance after asciminib progression represents an evolving clinical challenge requiring additional research and experience accumulation.

Dr. Zeidner shares similar approaches emphasizing resistance mutation testing to guide selection when applicable. He typically avoids backward sequencing (imatinib after second-generation failure) and acknowledges growing uncertainty about post-asciminib treatment strategies due to limited clinical experience and data availability.

Both physicians recognize the evolving treatment landscape with investigational agents including additional allosteric inhibitors and novel mechanisms potentially transforming relapsed/refractory CML management. The field's renewed complexity after apparent stagnation creates exciting opportunities for improved patient outcomes through expanded therapeutic options.

The discussion emphasizes continuing research needs to optimize treatment sequencing, understand resistance mechanisms, and develop strategies for achieving treatment-free remission in larger patient populations. Ongoing clinical trials and biological investigations will inform future treatment paradigms and potentially expand cure possibilities for patients with CML across diverse clinical scenarios.